Lv4
438 积分 2021-10-14 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3天前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC
2个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
2个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
4个月前
已完结
Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
5个月前
已关闭
Leveraging Artificial Intelligence to Transform Thoracic Radiology for Lung Nodules and Lung Cancer
5个月前
已关闭
Artificial Intelligence–Driven Three‐Dimensional Reconstruction in Lung Cancer Surgery: Current Status and Future Perspectives
5个月前
已完结
Artificial intelligence in lung cancer: from diagnosis to therapy
5个月前
已完结
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial
6个月前
已完结
皖公网安备34019202002308
